Dr James Spicer leads a well resourced Early Phase Unit working on a large portfolio of Phase I trials

The team has experience in first in man studies, extensive PK studies and bringing in-house King’s College London-designed molecules through to clinical trials embracing the whole ‘bench to bedside’ philosophy.

The unit also has history of strong collaboration, including taking part in the Olaparib programme, a series of trials looking at the safety of cancer therapy Olaparib in a number of settings in which all trials recruited to time and target. These trials completed the safety studies of Olaparib required for its first marketing authorisation and general availability to patients. The trials were run throughout 2014/15 in collaboration with Astra Zeneca and contract research organisation Quintiles, which has a dedicated clinical trials unit within Guys Hospital.